Brought to you by 
Sarepta licenses, options Duchenne's gene therapy programs from Nationwide Children's; later exercised
03 Jan 2020
Executive Summary
Sarepta Therapeutics Inc. signed concurrent agreements to research and develop two preclinical Duchenne muscular dystrophy (DMD) gene therapy candidates in collaboration with Nationwide Children's Hospital, exclusively licensing the institution's Galgt2 (beta1, 4-N- acetylgalactosamine galactosyltransferase) program and also securing an exclusive option for Nationwide's microdystrophin program.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sarepta licenses, options Duchenne's gene therapy programs from Nationwide Children's; later exercised
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice